Vmn2r103 Inhibitors
Vmn2r103 inhibitors pertain to a group of chemical agents designed to interact with the Vmn2r103 receptor. Vmn2r103 is one of the many receptors from the Vomeronasal type-2 receptor (V2R) family, which are a subclass of G protein-coupled receptors (GPCRs). These receptors are typically implicated in the detection of pheromones, compounds that serve as chemical signals between individuals of the same species, affecting various physiological and behavioral responses. The V2Rs are predominantly found in the vomeronasal organ (VNO) of the olfactory system, which is particularly well-developed in many vertebrates and is involved in non-volatile pheromone detection. The Vmn2r103 receptor, like other members of its family, participates in the complex process of chemosensation, where it binds specific ligands that are often related to social communication cues. Inhibitors of Vmn2r103 are molecules that can bind to this receptor and block its interaction with its natural ligands, thus inhibiting the usual signal transduction pathways that would follow receptor activation.
The development of Vmn2r103 inhibitors arises from an intricate understanding of molecular recognition and binding affinity. These inhibitors are designed based on the receptor's structure and the chemical nature of its ligand-binding domain. The specificity of Vmn2r103 inhibitors is critical; they must selectively bind to the Vmn2r103 receptor without significantly affecting other receptors, especially those within the same family, to avoid off-target effects. This specificity is achieved through a careful examination of the receptor's binding site and the design of molecules that can effectively compete with natural ligands. The interaction between the Vmn2r103 receptor and its inhibitors typically involves a combination of non-covalent forces, such as hydrogen bonds, hydrophobic interactions, and van der Waals forces, which altogether contribute to the affinity and selectivity of the inhibitors. Through the modulation of the receptor's activity, Vmn2r103 inhibitors can influence the receptor's normal function, which is rooted in the biochemical cascade of events triggered by ligand-receptor interactions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine is a natural compound known to affect the G-protein-coupled receptor (GPCR) signaling pathway. By binding to and stabilizing the inactive conformation of certain GPCRs, quinine can indirectly inhibit Vmn2r103, which is a member of the GPCR family, leading to decreased receptor activity. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, structurally related to quinine, also affects GPCR signaling. It can block the GPCR-associated ion channels or alter the receptor conformation, potentially reducing the functional activity of Vmn2r103 by preventing its proper response to ligands. | ||||||
Lidocaine | 137-58-6 | sc-204056 sc-204056A | 50 mg 1 g | $51.00 $131.00 | ||
Lidocaine can block voltage-gated sodium channels, which are essential for action potential propagation in neurons. By inhibiting these channels, lidocaine could decrease the neuronal activity that modulates the signaling pathways in which Vmn2r103 is involved. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is a calcium channel blocker that can reduce the intracellular calcium levels. Since GPCR signaling, including Vmn2r103's activity, often results in calcium-mediated intracellular effects, verapamil can indirectly inhibit Vmn2r103 by diminishing the calcium-dependent signaling cascades. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol is a beta-adrenergic receptor antagonist that can interfere with GPCR signaling. Although not specific to Vmn2r103, it may reduce the overall excitatory signaling within the pathways Vmn2r103 is involved with, leading to decreased receptor activity. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan is an angiotensin II receptor antagonist that inhibits GPCR signaling. By blocking this specific pathway, losartan may indirectly decrease the functional activity of other GPCRs, including Vmn2r103, by modulating the receptor's cellular environment. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
Cimetidine, a histamine H2 receptor antagonist, can inhibit GPCR-related gastric acid secretion. Although its primary action is not on Vmn2r103, the alteration in GPCR-mediated pathways could result in a decrease in Vmn2r103 signaling due to changes in cellular conditions. | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $82.00 $333.00 | 1 | |
Ondansetron is a serotonin 5-HT3 receptor antagonist that impacts GPCR signaling. By inhibiting one of the GPCR pathways, it could indirectly influence the activity of Vmn2r103 by altering the receptor's signaling environment. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Atropine, a competitive antagonist for the muscarinic acetylcholine receptors, can indirectly inhibit Vmn2r103 by modulating GPCR signaling pathways. This may lead to a reduction in Vmn2r103's functionality due to cross-talk between GPCR pathways. | ||||||
Diphenhydramine hydrochloride | 147-24-0 | sc-204729 sc-204729A sc-204729B | 10 g 25 g 100 g | $52.00 $84.00 $124.00 | 4 | |
Diphenhydramine is an antihistamine that blocks H1 histamine receptors, another class of GPCRs. By inhibiting these receptors, it could indirectly influence the signaling environment of Vmn2r103, leading to decreased activity. | ||||||